scholarly journals TWIST1 expression and clinical significance in type I endometrial cancer and premalignant lesions

Medicine ◽  
2020 ◽  
Vol 99 (48) ◽  
pp. e23397
Author(s):  
Junhua Shen ◽  
Qin Chen ◽  
Na Li ◽  
Xiaoxia Bai ◽  
Fenfen Wang ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Clinical Significance ◽  
Premalignant Lesions ◽  
Type I ◽  
Twist1 Expression

The Incidence and Clinical Significance of the Micrometastases in the Sentinel Lymph Nodes During Surgical Staging for Early Endometrial Cancer

2015 ◽  
Vol 25 (4) ◽  
pp. 673-680 ◽  
Author(s):  
Domenico Ferraioli ◽  
Nicolas Chopin ◽  
Frederic Beurrier ◽  
Nicolas Carrabin ◽  
Annie Buenerd ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Clinical Significance ◽  
Prognostic Significance ◽  
Case Series ◽  
Lymph Node Status ◽  
Type I ◽  
Gynecology And Obstetrics ◽  
Histopathologic Features

IntroductionThe status of regional node remains one of the most important factors to guide adjuvant therapy in endometrial cancer (EC). Pelvic recurrence occurs in up to 15% of early EC patients with negative pelvic lymph nodes (LNs). The prognostic significance of detecting micrometastases (μM) in LN is debated. This retrospective case-control study performed in the Oncological Gynecology Department in Lyon between December 1998 and June 2012 reports the incidence and the clinical significance of μM detected during ultrastaging of negative sentinel lymph node (SLN) in EC.Patients and MethodsNinety-three patients affected by type I and II EC were submitted to surgery with SLN. Dual-labeling method was used to detect SLN. All the SLNs were subjected to ultrastaging researching μM. The patients with a locoregional or distant relapse represented the case-series (CS). The patients without locoregional or distant recurrences were the case-controls (CC).They were matched (1:2 ratio) according to age, International Federation of Gynecology and Obstetrics stage, and histopathologic features.ResultsTen patients presenting a relapse represented CS. In the remaining 83 patients without recurrence, 20 CC were individualized. The detection rate of SLN per hemipelvis was of 17 (85%) of 20 hemipelvis and of 33 (82.5%) of 40 hemipelvis for CS and CC, respectively. Two SLN of CS arm were positives at frozen section. One of the 8 patients of CS arm with negative SLNs was positive for μM by immunohistochemistry analysis.ConclusionsLymph node status is one of the most important histopathologic features to determine the adjuvant treatment. The SLN technique could be proposed in selected patients affected by early EC. The μM in SLN could be researched and could help to modulate the following treatment. The multicenter study must be performed to clarify the optimal method of research of SLN in EC and the significance of μM in the LN.

scholarly journals ALDH1 expression predicts progression of premalignant lesions to cancer in Type I endometrial carcinomas

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Vei Mah ◽  
Yahya Elshimali ◽  
Alison Chu ◽  
Neda A. Moatamed ◽  
Jamar P. Uzzell ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Endometrial Hyperplasia ◽  
Prognostic Indicator ◽  
Premalignant Lesions ◽  
Stem Cell Marker ◽  
Type I ◽  
Clinical Value ◽  
Aldh1 Expression ◽  
Estrogen Stimulation ◽  
Endometrial Carcinomas

AbstractIn type 1 endometrial cancer, unopposed estrogen stimulation is thought to lead to endometrial hyperplasia which precedes malignant progression. Recent data from our group and others suggest that ALDH activity mediates stemness in endometrial cancer, but while aldehyde dehydrogenase 1 (ALDH1) has been suggested as a putative cancer stem cell marker in several cancer types, its clinical and prognostic value in endometrial cancer remains debated. The aim of this study was to investigate the clinical value of ALDH1 expression in endometrial hyperplasia and to determine its ability to predict progression to endometrial cancer. Interrogation of the TCGA database revealed upregulation of several isoforms in endometrial cancer, of which the ALDH1 isoforms collectively constituted the largest group. To translate its expression, a tissue microarray was previously constructed which contained a wide sampling of benign and malignant endometrial samples. The array contained a metachronous cohort of samples from individuals who either developed or did not develop endometrial cancer. Immunohistochemical staining was used to determine the intensity and frequency of ALDH1 expression. While benign proliferative and secretory endometrium showed very low levels of ALDH1, slightly higher expression was observed within the stratum basalis. In disease progression, cytoplasmic ALDH1 expression showed a step-wise increase between endometrial hyperplasia, atypical hyperplasia, and endometrial cancer. ALDH1 was also shown to be an early predictor of EC development, suggesting that it can serve as an independent prognostic indicator of patients with endometrial hyperplasia with or without atypia who would progress to cancer (p = 0.012).

scholarly journals Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0184576 ◽  
Author(s):  
Beata Kotowicz ◽  
Malgorzata Fuksiewicz ◽  
Joanna Jonska-Gmyrek ◽  
Alicja Berezowska ◽  
Jakub Radziszewski ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Prognostic Value ◽  
Serum Levels ◽  
Type I ◽  
Pretreatment Serum

scholarly journals Cancer susceptibility gene mutations in type I and II endometrial cancer

2019 ◽  
Vol 152 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Beverly Long ◽  
Jenna Lilyquist ◽  
Amy Weaver ◽  
Chunling Hu ◽  
Rohan Gnanaolivu ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Cancer Susceptibility ◽  
Susceptibility Gene ◽  
Gene Mutations ◽  
Type I ◽  
Cancer Susceptibility Gene

While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity

2018 ◽  
Vol 219 (4) ◽  
pp. 381.e1-381.e10
Author(s):  
Stephen Fiascone ◽  
Valery A. Danilack ◽  
Mary J. Kao ◽  
Michael Cohen ◽  
Kamaljeet Singh ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Medroxyprogesterone Acetate ◽  
Type I ◽  
Depot Medroxyprogesterone Acetate

scholarly journals Palliative treatment of endometrial cancer: what is the role of Anastrozole in elderly women?

2021 ◽  
Author(s):  
Barbara Gardella ◽  
Mattia Dominoni ◽  
Stefano Bogliolo ◽  
Chiara Cassani ◽  
Giulia Vittoria Carletti ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Palliative Treatment ◽  
Elderly Women ◽  
Endometrial Thickness ◽  
Average Rate ◽  
Female Genital Tract ◽  
Good Control ◽  
Common Disease ◽  
Type I ◽  
Progression Of Disease

Abstract Purpose: Type I endometrial cancer is a common disease which takes place in female genital tract. The aim of the work is to asset the feasibility and safety of anastrozole in the palliative treatment of endometrial cancer in elderly women not eligible to standard surgical treatment. Methods: eight patients with histological diagnosis of endometrial cancer were enrolled in this pilot study. Anastrozole was administered 1 mg daily per os after performing an accurate radiological mapping of the lesion. A questionnaire evaluated the quality of life of these patients. Results: the median age was 85 (range 80-88years). The endometrial cancer was confined to the uterus in all patients. No progression of disease was observed. A partial response to the therapy was reported in seven patients, while no response was reported in one patient. A decrease in the symptoms such as pain, vaginal bleeding and vaginal discomfort was reported, as well as no progression of disease. The endometrial thickness after twelve months has showed a reduction of 9.25 ± 4.77 mm. The average rate of follow-up was 18.25 months. Four women died for other reasons, none of them related to endometrial cancer. Evaluation of symptoms showed a significant reduction of appetite loss and insomnia, while a significant increase of global health status and fatigue was reported. Conclusion: our preliminary data reported that the palliative use of anastrozole may be a suitable therapy for a good control of early stages of endometrial cancer in inoperable elderly women, having a good compliance and tolerance.

scholarly journals High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Elisabet Aliagas ◽  
August Vidal ◽  
Laura Texidó ◽  
Jordi Ponce ◽  
Enric Condom ◽  
...  
Keyword(s):  
Gene Expression ◽  
Endometrial Cancer ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Tumor Grade ◽  
Type I ◽  
Type Ii ◽  
Extracellular Adenosine ◽  
Serous Tumors ◽  
Female Genital

One of the strategies used by tumors to evade immunosurveillance is the accumulation of extracellular adenosine, which has immunosupressive and tumor promoting effects. The study of the mechanisms leading to adenosine formation at the tumor interstitium are therefore of great interest in oncology. The dominant pathway generating extracellular adenosine in tumors is the dephosphorylation of ATP by ecto-nucleotidases. Two of these enzymes acting sequentially, CD39 and CD73, efficiently hydrolyze extracellular ATP to adenosine. They have been found to play a crucial role in a variety of tumors, but there were no data concerning endometrial cancer, the most frequent of the invasive tumors of the female genital tract. The aim of the present work is to study the expression of CD39 and CD73 in human endometrial cancer. We have analyzed protein and gene expression, as well as enzyme activity, in type I endometrioid adenocarcinomas and type II serous adenocarcinomas and their nonpathological endometrial counterparts. High levels of both enzymes were found in tumor samples, with significantly increased expression of CD39 in type II serous tumors, which also coincided with the higher tumor grade. Our results reinforce the involvement of the adenosinergic system in cancer, emphasizing the relevance of ecto-nucleotidases as emerging therapeutic targets in oncology.

EVALUATION OF MYOMETRIAL INVASION AND CERVICAL INVOLVEMENT IN TYPE I ENDOMETRIAL CANCER USING DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING

2020 ◽  
pp. 4-6
Author(s):  
HARIYONO WINARTO ◽  
BRIAN PRIMA ARTHA ◽  
SAHAT B. MATONDANG ◽  
TANTRI HELLYANTI ◽  
ARIA KEKALIH
Keyword(s):  
Magnetic Resonance Imaging ◽  
Endometrial Cancer ◽  
Magnetic Resonance ◽  
Cancer Patients ◽  
Myometrial Invasion ◽  
Type I ◽  
Resonance Imaging ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging ◽  
Cervical Involvement

Objective: Surgical procedure and adjuvant treatment of type I endometrial cancer were affected by some variables assessed preoperatively. Diffusion-weighted magnetic resonance imaging (DWI) is a promising modality in evaluating myometrial invasion and cervical involvement, investigating the diagnostic values of DWI in assessing myometrial invasion and cervical involvement. Methods: A cross-sectional study was conducted. This study involved all type I endometrial cancer patients in Dr. Cipto Mangunkusumo Hospital from April 2016 until April 2019. The depth of myometrial invasion and cervical involvement was examined using 1.5-T MR unit. The result was compared to the surgical pathologic findings as the reference standard. Results: 34 types I endometrial cancer patients were enrolled in this study. The sensitivity of DWI in evaluating myometrial invasion and cervical involvement in type I endometrial cancer was 94.12% and 57.14%, while the specificity was 64.71% and 92.59%, respectively. Conclusion: DWI can provide reliable prognostic variable information about the myometrial invasion and cervical involvement in the preoperative preparation of endometrial cancer patients.

Sign in / Sign up

Export Citation Format

Share Document